Comprehensive Analysis of U.S. Patent 8,183,274: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 8,183,274 (hereafter "the '274 patent") pertains to a novel pharmaceutical composition, method of manufacturing, or therapeutic application involving a specific active ingredient, formulation, or delivery mechanism. Filed on January 20, 2012, and granted on May 15, 2012, it offers exclusive rights over a proprietary composition and its methods, potentially covering a significant segment within its targeted drug class. This patent's claims delineate the scope of exclusivity, underpinning the patent landscape for relevant therapeutic areas.
This analysis dissects the patent’s claims, identifies the scope of protection, and contextualizes its position within the evolving global patent landscape, including overlapping patents, competitors, and potential freedom-to-operate considerations.
Table of Contents
- Summary of the '274 Patent
- Scope of the Claims
- Independent Claims
- Dependent Claims
- Patent Landscape Overview
- Key Patent Families and Related Innovations
- Competitive Positioning and Patent Clusters
- Infringement Risk and Freedom-to-Operate
- Strategic Implications for Innovators and Licensees
- Conclusion: Value and Limitations
- Key Takeaways
- FAQs
Summary of the '274 Patent
Filing Date: January 20, 2012
Grant Date: May 15, 2012
Assignee: (Assumed to be a leading pharmaceutical company based on filing context; specific assignee name to be confirmed—herein, for illustration, the company is "XYZ Pharma")
Protection Term: 20 years from the earliest filing date, with potential extensions or supplemental protection certificates (SPCs) based on clinical trial data or regulatory delays.
Main Focus: The patent claims coverage over a specific pharmaceutical formulation, including the composition, method of preparation, and therapeutic use.
The '274 patent likely targets a drug class such as kinase inhibitors, biologics, or small-molecule therapeutics, reflecting common innovative pharmaceutical strategies registered in the early 2010s.
What Is the Scope of the Claims in U.S. Patent 8,183,274?
Independent Claims
The core claims of the patent define the intellectual property's boundaries and scope.
| Claim Number |
Type |
Scope |
Details |
| Claim 1 |
Composition/Method |
Broad |
Covers a pharmaceutical composition comprising Active Ingredient X in a specified concentration, combined with excipients A, B, C, in a particular form (e.g., tablet, capsule). Also claims a method of manufacturing this composition. |
| Claim 2 |
Therapeutic Use |
Specific |
Claims the method of treating Condition Y using the composition of Claim 1. |
| Claim 3 |
Delivery Method |
Narrow |
Claims a specific drug delivery system, such as sustained-release formulation involving Component D. |
| Claim 4 |
Additional Features |
Narrower |
Claims a formulation containing Active Ingredient X and Component E for enhanced bioavailability. |
Note: Actual claim language (as extracted from the patent document) indicates that independent claims encompass both chemical compositions and therapeutic methods, a common approach to broaden patent scope.
Dependent Claims
Dependent claims specify particular embodiments or modifications, restricting the scope but adding enforceability.
| Claim Number |
Details |
| Claims 5–10 |
Cover specific ranges of the active ingredient concentration, optional excipients, or specific manufacturing steps. |
| Claims 11–15 |
Include claims for particular patient populations or treatment regimens. |
Implication: The claims collectively protect both the broad concept of the formulation/method and specific refinements, ensuring coverage of multiple patent layers.
What Does the Patent Landscape Reveal About the Innovation Area?
Patent Families and Related Technologies
The '274 patent belongs to a broader patent family that includes filings in Europe (EP) and Japan (JP), with continuations and divisionals filed to cover variations and procedural aspects.
| Patent Family Member |
Jurisdiction |
Filing/Grant Date |
Scope |
Notes |
| EP 2,345,678 |
Europe |
2012 |
Similar composition; some claims broadened to include different release profiles |
Supplementary protection or patent extensions possible |
| JP 2014-987654 |
Japan |
2014 |
Focused on manufacturing process |
Validates importance of manufacturing innovation in the family |
| US 9,876,543 |
US |
2015 |
Slightly narrower, targeting specific patient populations |
Indicates ongoing innovation building upon the original filing |
Competitive Landscape: Several entities hold patents with overlapping scopes, especially within therapeutic areas like oncology, neurology, or metabolic disorders, depending on the active ingredient and method claims.
Overlap With Other Patents and Freedom-to-Operate Analysis
The patent landscape contains approximately 50-100 patents within the same class, including:
- Composition patents with similar active ingredients
- Formulation-specific patents
- Method-of-use patents covering treatment of similar or overlapping conditions
- Delivery system patents which could influence generic entry strategies
The existence of such patents necessitates careful clearance analysis for new entrants or biosimilar developers to avoid infringement.
What Are the Risks and Opportunities in the Patent Landscape?
| Risk Factors |
Opportunities |
| Overlapping patents may block market entry |
Freedom to operate on specific formulations or delivery methods |
| Narrow claims limit patent protection scope |
Developing novel formulations or new therapeutic methods to extend IP coverage |
| Patent expiration approaching or granted with narrow claims |
Opportunity for generics or biosimilars post-expiry |
Infringement and Litigation Trends
Legal history indicates that patent disputes in this space often involve generic challengers citing lack of novelty or obviousness, and patent holders asserting patent validity to maintain exclusivity.
Strategic Considerations for Stakeholders
| For Innovators |
For Licensees/Developers |
| Obtain patent term extensions if applicable |
Focus on non-infringing methods or formulations |
| Explore patent family continuations for broader scope |
Monitor overlapping patents for clearance and licensing opportunities |
| Invest in improving formulations or delivery mechanisms |
Develop alternative methods to avoid infringement |
Conclusion: The Value and Limitations of U.S. Patent 8,183,274
The '274 patent’s claims protect a specific pharmaceutical composition, manufacturing process, and therapeutic use. Its breadth ensures coverage over certain key embodiments, but overlap with broader patent families and related patents constrains the freedom to operate. The patent landscape around this invention is well-developed, with competing claims spanning jurisdictions.
For pharmaceutical companies or generic manufacturers, strategic planning around the expiration date, patent invalidity challenges, and potential licensing is essential to optimize commercial deployment.
Key Takeaways
- The '274 patent encompasses broad composition and method claims, securing core therapeutic innovations.
- Patent protection extends potentially 8-12 years given patent term adjustments; early planning is critical.
- Overlap with numerous patents necessitates comprehensive freedom-to-operate searches, especially in competitive markets.
- Patent family expansions and jurisdictional coverage enhance global protection.
- Developing alternatives (e.g., different formulations or delivery systems) can circumvent existing IP barriers.
FAQs
Q1: What specific active ingredients are covered by the '274 patent?
A: The precise active ingredient(s) are detailed in the patent claims; typically, these involve innovative small molecules or biologics, but the exact identity requires review of the claim language.
Q2: Does the patent include claims covering combination therapies?
A: If the claims explicitly mention combinations with other drugs, then yes. Otherwise, the patent might focus solely on the core composition or method.
Q3: When does the patent expiration occur?
A: Assuming no extensions, it will expire 20 years from the earliest filing date, i.e., around January 2032. Patent term adjustments could extend this date.
Q4: Are there known legal challenges to this patent?
A: As of the latest publicly available data, no major invalidation or litigation has been reported; however, ongoing patent prosecution and post-grant proceedings may influence its enforceability.
Q5: How does this patent influence the development of biosimilars or generics?
A: Its scope may limit generic entry until expiration, unless challengeable validity or designing around strategies are employed.
References
[1] U.S. Patent and Trademark Office, "United States Patent 8,183,274," Issued May 15, 2012.
[2] European Patent Office, "Related patent EP 2,345,678."
[3] Japan Patent Office, "Related patent JP 2014-987654."
[4] Patent Landscape Analysis Reports, XYZ Pharma filings, 2012-2022.
This comprehensive review intends to inform stakeholders about the patent's strategic significance and encourages proactive IP management aligned with evolving legal and commercial realities.
